SCHEMBL4620484

SCHEMBL4620484

NC(=S)Nc1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
GAA P10253 2/20 0.45
LMNA P02545 1/20 0.45
ALOX12 P18054 1/20 0.45
IDO1 P14902 1/20 0.41
KMT2A Q03164 2/20 0.39
RAB9A P51151 2/20 0.39
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 1/20 0.39
CYP3A4 P08684 1/20 0.39
RECQL P46063 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11655477 0.83 CYP1A2 (0.44) ALDH1A1MAPTGAALMNAKMT2A
SCHEMBL10609608 0.83 KMT2A (0.37) ALDH1A1MAPTGAALMNAALOX12
SCHEMBL5427784 0.78 IDO1 (0.62) ALDH1A1MAPTGAALMNAIDO1
SCHEMBL18550693 0.78 GAA (0.47) ALDH1A1MAPTGAALMNAALOX12
SCHEMBL12394016 0.78 KDM4E (0.37) ALDH1A1MAPTLMNAALOX12KMT2A
SCHEMBL9723073 0.78 ALDH1A1 (0.49) ALDH1A1MAPTGAAKMT2ARAB9A
SCHEMBL374388 0.77 NPC1 (0.48) ALDH1A1MAPTGAALMNAKMT2A
SCHEMBL5520771 0.77 KMT2A (0.39) ALDH1A1MAPTGAALMNAALOX12
SCHEMBL3264509 0.77 GAA (0.50) ALDH1A1MAPTGAALMNAKMT2A
SCHEMBL11883596 0.77 ALDH1A1 (0.39) ALDH1A1MAPTGAALMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263167-A1 METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-08-24 US disclosed
US-11700855-B2 Method for preventing or reducing growth of a microorganism on a surface IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-07-18 US disclosed
US-20230129765-A1 METHOD FOR PRODUCING POLYTHIOETHER COMPOUND DAICEL CORPORATION (JP) 2023-04-27 US disclosed
EP-4108705-A1 METHOD FOR PRODUCING POLYTHIOETHER COMPOUND Daicel Corporation (JP) 2022-12-28 EP disclosed
CN-115135697-A Process for producing polythioether compound 株式会社大赛璐 2022-09-30 CN disclosed
CN-113278149-A Process for producing polythioether compound 株式会社大赛璐 2021-08-20 CN disclosed
US-20210061670-A1 METHOD FOR PREVENTING OR REDUCING GROWTH OF A MICROORGANISM ON A SURFACE IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2021-03-04 US disclosed
US-10934176-B2 Methods of degrading organic pollutants and preventing or treating microbe using Bi2S3-CdS particles IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2021-03-02 US disclosed
CN-110590785-B Aminothiazole compound, preparation method thereof and application of aminothiazole compound in resisting enterovirus 71 武汉大学 2021-02-02 CN disclosed
US-20200102228-A1 METHODS OF DEGRADING ORGANIC POLLUTANTS AND PREVENTING OR TREATING MICROBE USING Bi2S3-CdS PARTICLES IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2020-04-02 US disclosed
EP-1320365-A4 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR BRISTOL MYERS SQUIBB CO (US) 2004-03-17 EP disclosed
US-6632831-B2 Such as: (2-(2,6-Dichloro-phenylamino)-4-oxo-4H-thiazol-5-ylidene)-acet ic acid methyl ester PFIZER INC. 2003-10-14 US disclosed
EP-1314426-A9 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY (US) 2003-09-17 EP disclosed
US-20030162779-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY 2003-08-28 US disclosed
EP-1320365-A1 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR Bristol-Myers Squibb Company (US) 2003-06-25 EP disclosed
WO-2003045384-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2003-06-05 WO disclosed
EP-1314426-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY (US) 2003-05-28 EP disclosed
US-6515005-B2 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders BRISTOL-MYERS SQUIBB COMPANY 2003-02-04 US disclosed
US-20020161019-A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor BRISTOL-MYERS SQUIBB COMPANY 2002-10-31 US disclosed
WO-2002024200-A1 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR BRISTOL-MYERS SQUIBB COMPANY (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161019-A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor CRH, CRHR1, CRHR2 ALDH1A1 1902/4885MAPT 2192/4885GAA 4045/4885
US-20030162779-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES BCAT1, BCAT2, ABAT ALDH1A1 812/4885MAPT 5/4885GAA 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.